Cytokinetics (CYTK) Short Interest Ratio & Short Volume $34.54 +1.41 (+4.26%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$34.40 -0.14 (-0.39%) As of 06/10/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Cytokinetics Short Interest DataCytokinetics (CYTK) has a short interest of 15.60 million shares, representing 13.36% of the float (the number of shares available for trading by the public). This marks a 7.73% increase in short interest from the previous month. The short interest ratio (days to cover) is 7.4, indicating that it would take 7.4 days of the average trading volume of 1.55 million shares to cover all short positions.Current Short Interest15,600,000 sharesPrevious Short Interest14,480,000 sharesChange Vs. Previous Month+7.73%Dollar Volume Sold Short$465.50 millionShort Interest Ratio7.4 Days to CoverLast Record DateMay 15, 2025Outstanding Shares119,427,000 sharesFloat Size116,740,000 sharesShort Percent of Float13.36%Today's Trading Volume2,006,308 sharesAverage Trading Volume1,552,459 sharesToday's Volume Vs. Average129% Short Selling Cytokinetics? Sign up to receive the latest short interest report for Cytokinetics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCYTK Short Interest Over TimeCYTK Days to Cover Over TimeCYTK Percentage of Float Shorted Over Time Cytokinetics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202515,600,000 shares $465.50 million +7.7%13.4%7.4 $29.84 4/30/202514,480,000 shares $620.32 million +3.8%12.5%6.6 $42.84 4/15/202513,950,000 shares $537.91 million -2.7%12.0%7.2 $38.56 3/31/202514,330,000 shares $575.92 million +0.8%12.4%7.9 $40.19 3/15/202514,220,000 shares $630.80 million +1.1%12.3%9 $44.36 2/28/202514,070,000 shares $647.22 million -6.6%12.2%9.6 $46.00 2/15/202515,070,000 shares $695.63 million +10.4%13.1%10.6 $46.16 1/31/202513,650,000 shares $675.13 million -2.7%12.0%10.1 $49.46 1/15/202514,030,000 shares $657.59 million +2.3%12.4%11.6 $46.87 12/31/202413,710,000 shares $644.92 million -0.2%12.1%11.8 $47.04 Get the Latest News and Ratings for CYTK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. 12/15/202413,730,000 shares $667.96 million -2.1%12.1%11.7 $48.65 11/30/202414,030,000 shares $727.60 million -3.8%12.4%11.8 $51.86 11/15/202414,590,000 shares $732.71 million -7.0%12.8%11.8 $50.22 10/31/202415,690,000 shares $800.19 million +1.0%13.8%13.3 $51.00 10/15/202415,540,000 shares $860.61 million -10.3%13.7%12.8 $55.38 9/30/202417,320,000 shares $914.50 million -2.9%15.2%13.9 $52.80 9/15/202417,840,000 shares $996.90 million -2.0%15.7%12.9 $55.88 8/31/202418,210,000 shares $1.04 billion -2.3%16.0%12.8 $57.08 8/15/202418,630,000 shares $1.06 billion +4.5%16.4%9.4 $57.06 7/31/202417,830,000 shares $1.05 billion +2.1%15.7%8.7 $59.01 7/15/202417,460,000 shares $1.00 billion +0.5%15.8%8.8 $57.39 6/30/202417,380,000 shares $941.65 million +8.4%15.7%8.8 $54.18 6/15/202416,040,000 shares $865.04 million -2.3%14.5%8.3 $53.93 5/31/202416,420,000 shares $796.53 million +15.7%14.9%7.2 $48.51 5/15/202414,190,000 shares $858.50 million +3.8%14.1%6.5 $60.50 4/30/202413,670,000 shares $838.24 million -2.6%13.5%7.2 $61.32 4/15/202414,040,000 shares $954.72 million +6.1%13.9%6.9 $68.00 3/31/202413,230,000 shares $927.56 million -10.6%13.3%4.2 $70.11 3/15/202414,800,000 shares $964.81 million +1.9%14.9%3.7 $65.19 2/29/202414,530,000 shares $1.05 billion +5.1%14.6%3.9 $72.24 2/15/202413,830,000 shares $1.09 billion +1.8%14.6%3.9 $78.56 1/31/202413,580,000 shares $1.06 billion -1.2%14.5%3.9 $78.13 1/15/202413,750,000 shares $1.18 billion -8.8%14.7%3.9 $85.60 12/31/202315,080,000 shares $1.26 billion +2.9%16.1%5.1 $83.49 12/15/202314,660,000 shares $528.79 million +9.0%15.7%6.7 $36.07 11/30/202313,450,000 shares $450.31 million -1.8%14.4%8.9 $33.48 11/15/202313,690,000 shares $449.44 million -3.1%14.6%10.1 $32.83 10/31/202314,130,000 shares $492.57 million +2.8%15.4%11.6 $34.86 10/15/202313,750,000 shares $470.39 million +5.3%15.0%13 $34.21 9/30/202313,060,000 shares $384.75 million +4.1%14.2%14.2 $29.46Trump’s Exec Order #14154 could be a “Millionaire-Maker” (Ad)Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. For the moment, you can watch this interview free of charge – just click here. 9/15/202312,550,000 shares $429.59 million +8.1%13.7%15.7 $34.23 8/31/202311,610,000 shares $405.65 million +15.1%13.0%14.2 $34.94 8/15/202310,090,000 shares $330.04 million No Change11.3%12.4 $32.71 7/31/202310,090,000 shares $336.50 million -0.1%11.2%12.1 $33.35 7/15/202310,100,000 shares $352.79 million +1.5%11.3%11.8 $34.93 6/30/20239,950,000 shares $324.57 million +7.9%11.1%11.3 $32.62 6/15/20239,220,000 shares $326.76 million -2.5%10.3%10.2 $35.44 5/31/20239,460,000 shares $356.55 million +0.2%10.5%10.4 $37.69 5/15/20239,440,000 shares $367.69 million No Change10.5%9.4 $38.95 10/31/202211,340,000 shares $495.10 million -8.8%N/A9.9 $43.66 10/15/202212,440,000 shares $571.62 million +2.7%N/A10 $45.95 9/30/202212,110,000 shares $586.73 million +3.8%N/A9.5 $48.45 9/15/202211,670,000 shares $636.13 million -2.9%N/A7.7 $54.51 8/31/202212,020,000 shares $636.58 million -5.7%N/A8.1 $52.96 8/15/202212,740,000 shares $647.57 million +8.7%N/A9.2 $50.83 7/31/202211,720,000 shares $496.11 million -0.8%N/A8.6 $42.33 7/15/202211,810,000 shares $478.31 million +37.8%N/A9.4 $40.50 6/30/20228,570,000 shares $336.72 million +0.5%16.6%7.3 $39.29 6/15/20228,530,000 shares $350.67 million -2.0%16.5%10 $41.11 5/31/20228,700,000 shares $347.13 million -2.6%N/A10.1 $39.90 5/15/20228,930,000 shares $375.15 million +11.5%N/A9.6 $42.01 4/30/20228,010,000 shares $319.36 million +1.0%N/A7.9 $39.87 4/15/20227,930,000 shares $313.71 million +5.7%N/A7.9 $39.56 3/31/20227,500,000 shares $276.08 million +3.7%N/A6.9 $36.81 3/15/20227,230,000 shares $245.39 million -13.1%N/A6.7 $33.94 2/28/20228,320,000 shares $293.86 million +1.2%N/A7.7 $35.32 2/15/20228,220,000 shares $308.91 million +4.2%N/A7.5 $37.58 1/31/20227,890,000 shares $261.87 million -1.5%N/A7.7 $33.19 1/15/20228,010,000 shares $264.33 million +0.8%N/A0 $33.00 12/31/20217,950,000 shares $362.36 million -9.1%N/A8.8 $45.58 12/15/20218,750,000 shares $337.84 million +1.0%N/A10.1 $38.61 11/30/20218,660,000 shares $340.68 million -5.8%N/A10.1 $39.34 11/15/20219,190,000 shares $360.25 million -9.8%N/A10.6 $39.20 10/29/202110,190,000 shares $355.73 million +5.2%N/A12.3 $34.91 10/15/20219,690,000 shares $357.46 million -7.7%N/A11.3 $36.89 9/30/202110,500,000 shares $375.27 million -1.8%N/A5.5 $35.74 9/15/202110,690,000 shares $360.25 million -5.4%N/A5.7 $33.70 8/31/202111,300,000 shares $372.56 million -1.0%N/A6.2 $32.97 8/13/202111,410,000 shares $366.83 million -4.3%N/A6.5 $32.15 7/30/202111,920,000 shares $353.79 million +32.4%N/A6.6 $29.68 7/15/20219,000,000 shares $173.88 million +10.2%N/A5.2 $19.32 6/30/20218,170,000 shares $161.68 million -5.4%12.2%10.8 $19.79 6/15/20218,640,000 shares $192.50 million -4.9%12.9%11.8 $22.28 5/28/20219,080,000 shares $198.22 million -9.6%13.6%11.2 $21.83 5/14/202110,040,000 shares $253.31 million +6.9%N/A10.6 $25.23 4/30/20219,390,000 shares $247.80 million +2.6%N/A10.2 $26.39 4/15/20219,150,000 shares $221.98 million +1.9%N/A0 $24.26 3/31/20218,980,000 shares $200.52 million -7.7%N/A9.6 $22.33 3/15/20219,730,000 shares $222.04 million +5.5%N/A10.1 $22.82 2/26/20219,220,000 shares $183.02 million +0.2%N/A9.2 $19.85Trump’s Exec Order #14154 could be a “Millionaire-Maker” (Ad)Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. For the moment, you can watch this interview free of charge – just click here. 2/12/20219,200,000 shares $209.39 million -3.7%N/A9.8 $22.76 1/29/20219,550,000 shares $191 million -3.5%N/A9.3 $20.00 1/15/20219,900,000 shares $196.02 million +6.3%N/A9.6 $19.80 12/31/20209,310,000 shares $189.55 million +12.7%N/A7.4 $20.36 12/15/20208,260,000 shares $175.44 million -7.8%N/A4.8 $21.24 11/30/20208,960,000 shares $153.66 million +1.8%N/A5.4 $17.15 11/15/20208,800,000 shares $145.38 million -6.4%N/A5.5 $16.52 10/30/20209,400,000 shares $145.61 million +3.3%N/A6.1 $15.49 10/15/20209,100,000 shares $150.06 million +3.6%N/A6 $16.49 9/30/20208,780,000 shares $190.09 million +22.3%N/A5.7 $21.65 9/15/20207,180,000 shares $166.72 million -3.8%N/A7.6 $23.22 8/31/20207,460,000 shares $178.74 million +3.5%N/A8.2 $23.96 8/14/20207,210,000 shares $162.37 million -1.2%N/A8.3 $22.52 7/31/20207,300,000 shares $157.83 million -9.2%13.4%7.5 $21.62 7/15/20208,040,000 shares $224.16 million -1.7%14.8%8.2 $27.88 6/30/20208,180,000 shares $192.97 million +6.0%15.0%9.5 $23.59 6/15/20207,720,000 shares $167.76 million -6.3%14.2%8.9 $21.73 CYTK Short Interest - Frequently Asked Questions What is Cytokinetics' current short interest? Short interest is the volume of Cytokinetics shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 15,600,000 shares of CYTK short. 13.36% of Cytokinetics' shares are currently sold short. Learn More on Cytokinetics' current short interest. What is a good short interest ratio for Cytokinetics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CYTK shares currently have a short interest ratio of 7.0. Learn More on Cytokinetics's short interest ratio. Which institutional investors are shorting Cytokinetics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cytokinetics: Jane Street Group LLC, Exome Asset Management LLC, Goldman Sachs Group Inc., Parallax Volatility Advisers L.P., Caption Management LLC, Nomura Holdings Inc., HAP Trading LLC, PEAK6 LLC, Jane Street Group LLC, Walleye Trading LLC, Walleye Capital LLC, Simplex Trading LLC, Wolverine Asset Management LLC, and Citigroup Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Cytokinetics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 13.36% of Cytokinetics' floating shares are currently sold short. Is Cytokinetics' short interest increasing or decreasing? Cytokinetics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 15,600,000 shares, an increase of 7.7% from the previous total of 14,480,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Cytokinetics' float size? Cytokinetics currently has issued a total of 119,427,000 shares. Some of Cytokinetics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cytokinetics currently has a public float of 116,740,000 shares. How does Cytokinetics' short interest compare to its competitors? 13.36% of Cytokinetics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Cytokinetics: Intra-Cellular Therapies, Inc. (2.58%), Genmab A/S (0.45%), Summit Therapeutics Inc. (29.82%), Dr. Reddy's Laboratories Limited (1.83%), Ascendis Pharma A/S (10.33%), Moderna, Inc. (19.64%), Viatris Inc. (4.53%), Qiagen (2.81%), Blueprint Medicines Co. (9.26%), Roivant Sciences Ltd. (11.23%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($29.20 billion), Strategy Incorporated ($10.88 billion), iShares 20+ Year Treasury Bond ETF ($10.04 billion), Capital One Financial Co. ($5.51 billion), Charter Communications, Inc. ($5.00 billion), Super Micro Computer, Inc. ($4.43 billion), Apollo Global Management, Inc. ($4.02 billion), Hims & Hers Health, Inc. ($3.65 billion), VanEck Semiconductor ETF ($3.27 billion), and Coinbase Global, Inc. ($3.10 billion). View all of the most shorted stocks. What does it mean to sell short Cytokinetics stock? Short selling CYTK is an investing strategy that aims to generate trading profit from Cytokinetics as its price is falling. CYTK shares are trading up $1.41 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cytokinetics? A short squeeze for Cytokinetics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CYTK, which in turn drives the price of the stock up even further. How often is Cytokinetics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CYTK, twice per month. The most recent reporting period available is May, 15 2025. More Short Interest Resources from MarketBeat Related Companies ITCI Short Interest Data GMAB Short Interest Data SMMT Short Interest Data RDY Short Interest Data ASND Short Interest Data MRNA Short Interest Data VTRS Short Interest Data QGEN Short Interest Data BPMC Short Interest Data ROIV Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CYTK) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYTK Stock Free CYTK Stock Alerts